| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS10000171 | HBV | ENSG00000091879.14 | protein_coding | ANGPT2 | No | No | 285 | O15123 |
| TVIS30009474 | HIV | ENSG00000091879.14 | protein_coding | ANGPT2 | No | No | 285 | O15123 |
| TVIS30084026 | HIV | ENSG00000091879.14 | protein_coding | ANGPT2 | No | No | 285 | O15123 |
| TVIS20000688 | HPV | ENSG00000091879.14 | protein_coding | ANGPT2 | No | No | 285 | O15123 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | ANGPT2 |
|---|---|
| DrugBank ID | DB15303 |
| Drug Name | Faricimab |
| Target ID | BE0010028 |
| UniProt ID | O15123 |
| Regulation Type | antagonist |
| PubMed IDs | 27742718 |
| Citations | Regula JT, Lundh von Leithner P, Foxton R, Barathi VA, Cheung CM, Bo Tun SB, Wey YS, Iwata D, Dostalek M, Moelleken J, Stubenrauch KG, Nogoceke E, Widmer G, Strassburger P, Koss MJ, Klein C, Shima DT, Hartmann G: Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases. EMBO Mol Med. 2016 Nov 2;8(11):1265-1288. doi: 10.15252/emmm.201505889. Print 2016 Nov. |
| Groups | Approved; Investigational |
| Direct Classification | Peptides |
| SMILES | |
| Pathways | |
| PharmGKB | |
| ChEMBL |
